EpiAxis enters strategic partnership with UHN

EpiAxis enters strategic partnership with UHN

EpiAxis Therapeutics and University Health Network (UHN) - Canada’s largest and leading research hospital - have entered into a collaboration to study a new approach to prostate cancer treatment. As part of the agreement, EpiAxis Therapeutics will supply its lead...

read more
EpiAxis highlights – July 2022

EpiAxis highlights – July 2022

July offered valuable opportunities for EpiAxis Therapeutics to update venture capitalists, corporate investors, private investors and investment bankers on its latest epigenetic findings. The company is currently working with The Sage Group to raise US$12million to...

read more

 

Professor Sudha Rao